Clinical evaluation of 4′-epi-doxorubicin in advanced solid tumors

Gioacchino Robustelli Della Cuna, Lorenzo Pavesi, Piero Preti, Fabrizio Ganzina

Research output: Contribution to journalArticle

Abstract

A Phase II clinical evaluation of 4′-epi-doxorubicin has been carried out in 100 patients with various types of solid tumors. Hematopoietic toxicity was dose-limiting but reversible and of mild to moderate degree. Other acute toxic manifestations such as vomiting and alopecia were qualitatively similar to those usually reported for doxorubicin, but lower in frequency and less severe. A number of responding patients received cumulative doses of 4′-epi-doxorubicin in excess of 500 mg/m2. One patient manifested reversible clinical congestive heart failure at cumulative dose of 1,080 mg/m2. Therapeutic activity has been observed in breast carcinoma, in rectal carcinoma and in melanoma. In chemoresistant tumors as rectal cancer and melanoma 4′-epi-doxorubicin deserves further study.

Original languageEnglish
Pages (from-to)349-353
Number of pages5
JournalInvestigational New Drugs
Volume1
Issue number4
DOIs
Publication statusPublished - Dec 1983

Fingerprint

Epirubicin
Melanoma
Neoplasms
Poisons
Alopecia
Rectal Neoplasms
Doxorubicin
Vomiting
Heart Failure
Breast Neoplasms
Carcinoma
Therapeutics

Keywords

  • 4′-epi-doxorubicin
  • clinical toxicity
  • doxorubicin
  • therapeutic efficacy

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Clinical evaluation of 4′-epi-doxorubicin in advanced solid tumors. / Cuna, Gioacchino Robustelli Della; Pavesi, Lorenzo; Preti, Piero; Ganzina, Fabrizio.

In: Investigational New Drugs, Vol. 1, No. 4, 12.1983, p. 349-353.

Research output: Contribution to journalArticle

Cuna, Gioacchino Robustelli Della ; Pavesi, Lorenzo ; Preti, Piero ; Ganzina, Fabrizio. / Clinical evaluation of 4′-epi-doxorubicin in advanced solid tumors. In: Investigational New Drugs. 1983 ; Vol. 1, No. 4. pp. 349-353.
@article{0faa9e1e5d51478d9056d48ce69ae1c6,
title = "Clinical evaluation of 4′-epi-doxorubicin in advanced solid tumors",
abstract = "A Phase II clinical evaluation of 4′-epi-doxorubicin has been carried out in 100 patients with various types of solid tumors. Hematopoietic toxicity was dose-limiting but reversible and of mild to moderate degree. Other acute toxic manifestations such as vomiting and alopecia were qualitatively similar to those usually reported for doxorubicin, but lower in frequency and less severe. A number of responding patients received cumulative doses of 4′-epi-doxorubicin in excess of 500 mg/m2. One patient manifested reversible clinical congestive heart failure at cumulative dose of 1,080 mg/m2. Therapeutic activity has been observed in breast carcinoma, in rectal carcinoma and in melanoma. In chemoresistant tumors as rectal cancer and melanoma 4′-epi-doxorubicin deserves further study.",
keywords = "4′-epi-doxorubicin, clinical toxicity, doxorubicin, therapeutic efficacy",
author = "Cuna, {Gioacchino Robustelli Della} and Lorenzo Pavesi and Piero Preti and Fabrizio Ganzina",
year = "1983",
month = "12",
doi = "10.1007/BF00177421",
language = "English",
volume = "1",
pages = "349--353",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "4",

}

TY - JOUR

T1 - Clinical evaluation of 4′-epi-doxorubicin in advanced solid tumors

AU - Cuna, Gioacchino Robustelli Della

AU - Pavesi, Lorenzo

AU - Preti, Piero

AU - Ganzina, Fabrizio

PY - 1983/12

Y1 - 1983/12

N2 - A Phase II clinical evaluation of 4′-epi-doxorubicin has been carried out in 100 patients with various types of solid tumors. Hematopoietic toxicity was dose-limiting but reversible and of mild to moderate degree. Other acute toxic manifestations such as vomiting and alopecia were qualitatively similar to those usually reported for doxorubicin, but lower in frequency and less severe. A number of responding patients received cumulative doses of 4′-epi-doxorubicin in excess of 500 mg/m2. One patient manifested reversible clinical congestive heart failure at cumulative dose of 1,080 mg/m2. Therapeutic activity has been observed in breast carcinoma, in rectal carcinoma and in melanoma. In chemoresistant tumors as rectal cancer and melanoma 4′-epi-doxorubicin deserves further study.

AB - A Phase II clinical evaluation of 4′-epi-doxorubicin has been carried out in 100 patients with various types of solid tumors. Hematopoietic toxicity was dose-limiting but reversible and of mild to moderate degree. Other acute toxic manifestations such as vomiting and alopecia were qualitatively similar to those usually reported for doxorubicin, but lower in frequency and less severe. A number of responding patients received cumulative doses of 4′-epi-doxorubicin in excess of 500 mg/m2. One patient manifested reversible clinical congestive heart failure at cumulative dose of 1,080 mg/m2. Therapeutic activity has been observed in breast carcinoma, in rectal carcinoma and in melanoma. In chemoresistant tumors as rectal cancer and melanoma 4′-epi-doxorubicin deserves further study.

KW - 4′-epi-doxorubicin

KW - clinical toxicity

KW - doxorubicin

KW - therapeutic efficacy

UR - http://www.scopus.com/inward/record.url?scp=0020954459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020954459&partnerID=8YFLogxK

U2 - 10.1007/BF00177421

DO - 10.1007/BF00177421

M3 - Article

C2 - 6590532

AN - SCOPUS:0020954459

VL - 1

SP - 349

EP - 353

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 4

ER -